A detailed history of Hancock Whitney Corp transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Hancock Whitney Corp holds 9,236 shares of HRMY stock, worth $318,642. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,236
Previous 9,118 1.29%
Holding current value
$318,642
Previous $275,000 33.82%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$30.0 - $39.95 $3,540 - $4,714
118 Added 1.29%
9,236 $368,000
Q2 2024

Aug 13, 2024

SELL
$28.81 - $33.01 $41,169 - $47,171
-1,429 Reduced 13.55%
9,118 $275,000
Q1 2024

May 16, 2024

BUY
$29.93 - $35.06 $315,671 - $369,777
10,547 New
10,547 $354,000
Q4 2022

Nov 13, 2023

BUY
$45.4 - $60.91 $196,627 - $263,801
4,331 New
4,331 $238,000
Q4 2022

Feb 03, 2023

BUY
$45.4 - $60.91 $196,627 - $263,801
4,331 New
4,331 $239,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.04B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Hancock Whitney Corp Portfolio

Follow Hancock Whitney Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hancock Whitney Corp, based on Form 13F filings with the SEC.

News

Stay updated on Hancock Whitney Corp with notifications on news.